Clinically, low RASSF6 expression correlated with poorer overall survival in patients with luminal A and non-luminal HER2-positive cancers, underscoring its prognostic significance and potential utility as a biomarker of Hippo pathway integrity. This evidence concerns the gene ERBB2 and cancer.